A Phase 1 interventional study of DS-2330b PIB and Placebo in Hyperphosphatemia, sponsored by Daiichi Sankyo. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-25.
Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sevelamer in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. Sevelamer · Hyperphosphatemia.
Among the 12 studies testing sevelamer in Hyperphosphatemia, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is the only one in phase 1, and was the 12th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →None of the 12 studies testing sevelamer in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →
Sevelamer: first FDA approval 1998 (RENAGEL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2017.
This study's enrollment of 40 is below the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 45 across the 12 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 9 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
Daiichi Sankyo has 1 study filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing sevelamer in Hyperphosphatemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This three-part study will be performed with participants on chronic hemodialysis.
After screening, participants should expect the study to last about 21 days for Part A, and 46 days for Parts B and C.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Parts B and C only:
Exclusion Criteria:
Has any history, current condition, or drug use that per protocol or in the opinion of the investigator might compromise:
For Parts B and C only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB \[Treatment A1\] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form \[Treatment A2\] right after breakfast.
Drug: DS-2330b PIB · Drug: DS-2330b Tablet
On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form \[Treatment A2\] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB \[Treatment A1\] right after breakfast.
Drug: DS-2330b PIB · Drug: DS-2330b Tablet
Participants are given placebo three times daily \[Treatment B1\]
Drug: Placebo
Participants are given 400 mg of DS-2330b PIB three times daily \[Treatment B2\]
Drug: DS-2330b PIB
Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily \[Treatment B3\]
Drug: DS-2330b PIB · Drug: Sevelamer
Participants are given placebo along with 1.6 grams of sevelamer three times daily \[Treatment B4\]
Drug: Placebo · Drug: Sevelamer
Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily \[Treatment C\]
Drug: Sevelamer · Drug: DS-2330b Tablet
DS-2330b as powder in bottle with stock solution (PIB)
Placebo matching stock solution in bottle
Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
Also known as: Sevelamer carbonate
DS-2330b as tablet formulation
Part A, Period 1: Maximum concentration (Cmax) of DS-2330a
Time frame: Period 1, Pre-dose to 48 hours post-dose
Part A, Period 2: Cmax of DS-2330a
Time frame: Period 2, Pre-dose to 48 hours post-dose
Part A, Period 1: Time to maximum concentration (Tmax) of DS-2330a
Time frame: Period 1, Pre-dose to 48 hours post-dose
Part A, Period 2: Tmax of DS-2330a
Time frame: Period 2, Pre-dose to 48 hours post-dose
Part A, Period 1: Area under the drug concentration curve (AUC) for DS-2330a over 24 hours (AUC-24)
Time frame: Period 1, Pre-dose to 24 hours post-dose
Part A, Period 2: AUC for DS-2330a for DS-2330a over 24 hours (AUC-24)
Time frame: Period 2, Pre-dose to 24 hours post-dose
Part A, Period 1: AUC at the last observable concentration (AUClast) and to infinity (AUCinf) for DS-2330a
Categories (with the same unit of measure ng\*hr/mL): AUClast, AUCinf
Time frame: Period 1, Pre-dose to 48 hours post-dose
Part A, Period 2: AUClast and AUCinf for DS-2330a
Categories (with the same unit of measure ng\*hr/mL): AUClast, AUCinf
Time frame: Period 2, Pre-dose to 48 hours post-dose
Parts B and C: Serum phosphate (Pi) levels before hemodialysis
Time frame: within 15 days
All Parts: Number of trial participants with treatment-emergent adverse events (TEAEs)
TEAEs are adverse events (side effects) associated with taking an investigational product, whether or not they were caused by the investigational product. Clinically significant changes in physical exam findings, vital signs, electrocardiograms, clinical lab tests and thyroid function are recorded as TEAEs.
Time frame: through trial completion (about 15 months)
Parts B and C: Cmax of DS-2330a
Time frame: within 24 hours on Day 1
Parts B and C: Cmax of DS-2330a
Time frame: within 24 hours on Day 13
Parts B and C: Tmax of DS-2330a
Time frame: within 24 hours, Day 1
Parts B and C: Tmax of DS-2330a
Time frame: within 24 hours, Day 13
Parts B and C: AUC-24 for DS-2330a
Time frame: Day 1
Parts B and C: AUC-24 for DS-2330a
Time frame: Day 13
Parts B and C: AUCinf for DS-2330a
Time frame: Day 1
Parts B and C: AUCinf for DS-2330a
Time frame: Day 13
Parts B and C: Minimum concentration (Ctrough) of DS-2330a
Trough blood levels for DS-2330a will be collected before the morning dose (prior to breakfast)
Time frame: within 11 days
Part B: Dialysis clearance of DS-2330a
Time frame: on Day 11
Ran from Aug 2017 to primary completion in Jan 2019, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sevelamer